J&J Ordered To Pay $327M Over Risperdal Marketing

Law360, New York (June 3, 2011, 6:54 PM EDT) -- A South Carolina state court judge on Friday ordered a Johnson & Johnson subsidiary to pay $327 million for downplaying the links between its antipsychotic drug Risperdal and diabetes.

Judge Roger Couch announced the decision Friday, according to attorneys for the state, which brought the case over alleged problems with package inserts sent out with drug samples and “dear doctor” letters to more than 7,000 doctors.

The decision is one of several in several states to condemn Johnson & Johnson's allegedly shady marketing of Risperdal....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.